@chilunsin
CAP-1002 is a cell therapy. It is an allogeneic product, meaning it is manufactured from donor heart tissue and then stored until needed for use. CAP-1002 consists of allogeneic cardiosphere-derived cells, a unique population of cells that contains cardiac progenitor cells. It is thought to decrease inflammation and muscle degeneration while exerting positive effects on muscle regeneration, all of which may translate into patients retaining muscle function for a longer period of time
Not like us directly targeting Inflamation but who knows what trial outcomes are going to be
We dont hence the trial
We were not targeting increase in muscle mass but it looks like we could be onto it
Taken from the ppmd site
They are looking at improving multiple aspects of the disease
https://www.parentprojectmd.org/drug-development-pipeline/cap-1002/
When i said, side by side i was talking clinical advancement under regulatory guidance
- Forums
- ASX - By Stock
- PER
- For General Information
For General Information, page-2438
-
-
- There are more pages in this discussion • 1,090 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
10.0¢ |
Change
-0.005(4.76%) |
Mkt cap ! $90.15M |
Open | High | Low | Value | Volume |
11.0¢ | 11.0¢ | 10.0¢ | $52.56K | 502.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 176914 | 10.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
10.5¢ | 217753 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 176914 | 0.100 |
1 | 50000 | 0.099 |
1 | 100000 | 0.098 |
1 | 30927 | 0.097 |
1 | 1373 | 0.096 |
Price($) | Vol. | No. |
---|---|---|
0.105 | 217753 | 2 |
0.110 | 738750 | 8 |
0.115 | 1033419 | 5 |
0.120 | 178142 | 6 |
0.125 | 25000 | 1 |
Last trade - 16.10pm 18/09/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |